Albert Einstein College of Medicine

The Feinstein Institutes for Medical Research

The Feinstein Institute for Medical Research

Yeshiva University

Betty A Diamond

Peter Gregersen

Matthew D Scharff

Lior Brimberg

Simone Mader

Bruce D Gaynor

Philippe Valadon

Yousef Al-Abed

Subhransu Ray

Methods of diagnosis and methods of treatment and prevention for autism spectrum disorder are provided using decoy antigens to maternal brain-reactive antibodies.

Decoy antigens to maternal brain-reactive antibodies

Fusion proteins of C1q peptides and HMBG1 A-box or HMBG1 B-box, or C1q peptides and DWESY peptide are provided, and methods of use thereof.

C1q and HMGB1 fusion proteins and uses thereof

Inhibition of autism spectrum disorder using decoy antigens to maternal brain-reactive antibodies

Isolated C1q peptides, fusion proteins and compositions comprising such and fusion proteins comprising are provided. Isolated fusion proteins comprising XWXYXas defined herein and compositions comprising such are also provided. Methods of treating autoimmune disorders are provided.

C1q peptides and uses thereof

Small molecule compounds are provided for treating lupus as are methods of treating lupus using these compounds.

Compounds and methods for treatment of systemic lupus erythematosus

The present invention provides a method for identifying a peptide which binds to an anti-double stranded DNA antibody. The present invention also provides a class of peptides identified by the method of the present invention which bind to anti-double stranded DNA antibodies and compositions containing these peptides. The present invention also provides methods for the diagnosis and treatment of systemic lupus erythematosus utilizing the peptides of the present invention.

Peptides for detecting anti-double stranded DNA antibody and uses thereof

Peptides for the treatment and diagnosis of systemic lupus erythematosus

Peptides which bind to anti-double stranded DNA antibody

This invention relates to an NSO myeloma cell line which has increased fusion frequency, and to a method of producing said cell line. The NSO cell line of the invention, when fused with B cells, produces monoclonal antibody-secreting hybridoma which has increased resistance to death. In addition, the monoclonal antibodies secreted by said hybridomas have increased affinity for foreign antigens and for autoantigens.

Hybridoma-producing NSO myeloma cell line

The invention relates to monoclonal anti-idiotypic antibodies to human anti-DNA antibodies. Monoclonal, anti-idiotypic antibodies are produced using hybridoma technology. The antibodies are used as diagnostic reagents in methods to determine the presence of anti-native DNA antibodies in serum from patients suspected of having systemic lupus erythematosus.

Monoclonal antibodies reactive with shared idiotypes on human antibodies

The invention relates to monoclonal anti-idiotypic antibodies to human anti-DNA antibodies. Monoclonal, anti-idiotypic antibodies are produced using hybridoma technology. The antibodies are used as diagnostic reagents in methods to determine the presence of anti-native DNA antibodies in serum from patients suspected of having systemic lupus erythematosus, and as therapeutic reagents in methods to remove the anti-native DNA antibodies from the serum of patients with systemic lupus erythematosus.

Growing community of inventors

Bronx, NY, United States of America

Betty A Diamond